EDNRB
ENSG00000136160
Target class
GPCR
Chromosome
13
Approved drugs
6
Clinical candidates (approved and in development)
10
- Approved drugs
- 6
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Other names
- ETB
- Target name
- EDNRB
- Gene name
- Endothelin receptor type B
- Gene symbol
- EDNRB
- Protein name
- Endothelin receptor type B (ET-B) (ET-BR) (Endothelin receptor non-selective type)
- HSCR2
- HSCR
- Gene biotype
- Protein coding
- Gene family
- Endothelin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 52
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 73.2
- Tissue specificity (Gini)
- 0.411
- Tissue specificity (tau)
- 0.742
- KEGG gene identifiers
- hsa:1910
- Protein interaction confidence
- 0.874643
- Protein interaction partners
- 28
- R-HSA-375276
- R-HSA-416476
- R-HSA-9856649
- End position
- 77975529
- Start position
- 77895481
- Chromosome
- 13
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein. Note=internalized after activation by endothelins. .
- Plasma membrane
Publication evidence
- PubMed 28236341
- Tissue specificity (tau)
- 0.741883
- Expression inequality (Gini)
- 0.41083
Expression in transcripts per million
- Adipose - Visceral (Omentum)
- 73.2
- Lung
- 65.38
- Adipose - Subcutaneous
- 60.64
- Brain - Caudate (basal ganglia)
- 48.83
- Breast - Mammary Tissue
- 45.49
Expression in transcripts per million
- Adipose - Visceral (Omentum)73.2
- Lung65.38
- Adipose - Subcutaneous60.64
- Brain - Caudate (basal ganglia)48.83
- Breast - Mammary Tissue45.49
- Thyroid42.37
- Brain - Nucleus accumbens (basal ganglia)39.43
- Brain - Putamen (basal ganglia)35.77
- Cervix - Ectocervix31.63
- Brain - Substantia nigra31.21
- Brain - Amygdala28.4
- Fallopian Tube26.18
- Brain - Anterior cingulate cortex (BA24)25.76
- Adrenal Gland24.85
- Brain - Hypothalamus23.82
- Kidney - Medulla23.2
- Nerve - Tibial22.78
- Vagina22.2
- Bladder21.86
- Prostate21.47
- Uterus20.59
- Heart - Atrial Appendage19.93
- Cervix - Endocervix19.63
- Esophagus - Muscularis16.71
- Brain - Frontal Cortex (BA9)16.04
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0007166
- GO:0007194
- GO:0007200
- GO:0007399
- GO:0014826
- GO:0019722
- GO:0042310
- GO:0048246
- GO:0051248
- GO:0086100
Cellular components
- GO:0005886
- GO:0004962
- GO:0005515
- GO:0017046
decreased intestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased intestinal transit
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased gastric emptying
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastric emptying
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264cardiovascular malformations
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: cardiovascular malformations
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264increased then decreased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased then decreased heart rate
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased urine excretion
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased pain
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased pain
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264cell proliferation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cell proliferation
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264pulmonary hypertension
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pulmonary hypertension
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264increased blood pressure
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood pressure
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264left ventricular hypertrophy
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: left ventricular hypertrophy
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased then increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased then increased blood pressure
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264bronchoconstriction
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchoconstriction
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264decreased platelet aggregation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased platelet aggregation
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264craniofacial abnormalities
Effects
- Inhibition/Decrease/Downregulation: developmental toxicity
Studies
- preclinical: craniofacial abnormalities
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264glomerular and tubulointerstitial structural injury
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: glomerular and tubulointerstitial structural injury
- respiratory
- renal
- cardiovascular
- gastrointestinal
- blood
PubMed 28216264
receptor binding
Studies
- biochemical: NVS_GPCR_hETB, is one of one assay component(s) measured or calculated from the NVS_GPCR_hETB assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (294)
- (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
- (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
- A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients
- A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
- A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
- A Clinical Study to Find Out if Macitentan is Effective and Safe in Japanese Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
- A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
- A Long Term Safety Study With Atrasentan
- A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)
- A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
- A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
- A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin
- A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
- A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Drugs (14)
- Ambrisentan Endothelin receptor, ET-A/ET-B antagonist
- Aprocitentan Endothelin receptor, ET-A/ET-B antagonist
- Atrasentan
- Bosentan Endothelin receptor, ET-A/ET-B antagonist
- Clazosentan
- Darusentan Endothelin receptor ET-B antagonist
- Enrasentan Endothelin receptor ET-B antagonist
- Macitentan Endothelin receptor, ET-A/ET-B antagonist
- RG-7636 Endothelin receptor ET-B binding agent
- Ro-468443
- Sitaxentan Endothelin receptor, ET-A/ET-B antagonist
- Sitaxentan sodium Endothelin receptor, ET-A/ET-B antagonist
- Sovatelitide
- Tezosentan Endothelin receptor ET-B antagonist